Awaiting development: Guidance and quality standards

Showing 271 to 280 of 391

Guidance and quality standards awaiting development
Title	Type
Ritlecitinib for treating non-segmental vitiligo in people 12 years and over [ID6584]	Technology appraisal guidance
Rivaroxaban for treating chronic heart failure [ID1462]	Technology appraisal guidance
Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]	Technology appraisal guidance
Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy [TSID10764]	Technology appraisal guidance
Rucaparib with nivolumab for maintenance treatment of platinum-sensitive advanced ovarian, fallopian tube or peritoneal cancer after 1 therapy [TSID10763]	Technology appraisal guidance
Rusfertide for treating polycythaemia vera in people having phlebotomy [ID6709]	Technology appraisal guidance
Sabizabulin for treating COVID 19 [TSID11814]	Technology appraisal guidance
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6592]	Technology appraisal guidance
Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer [ID6433]	Technology appraisal guidance
Sacituzumab tirumotecan for treating advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma after 2 or more treatment lines [ID6723]	Technology appraisal guidance